ClinicalTrials.gg
Status unknownNCT03751306Updated Nov 27, 2018

Aerobic Exercise and Transcranial Low Laser Therapy in Patients With Central Nervous System Injury

An interventional study of Transcranial Photobiomodulation and Transcranial Photobiomodulation (Placebo) in Post Stroke, Post-Traumatic Headache and Spinal Injuries, sponsored by Universidade do Vale do Paraíba. Status unknown at 1 site in Brazil. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-11-27.

Sponsored by Universidade do Vale do Paraíba · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Nov 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Objective of this protocol will be to evaluate the parameters related to the function of the musculoskeletal and cardiorespiratory system, through a rehabilitation and training program for people with acquired central nervous system and multiple sclerosis. The study will consist of volunteers with acquired CNS lesions and multiple sclerosis of both sexes, between 18 and 85 years old, and who wander with or without aid devices, randomly divided into 3 groups: Group 1 (cardiopulmonary treatment), Group 2 (cardiopulmonary treatment and transcranial photobiomodulation application) and Group 3 (cardiopulmonary treatment and placebo laser). All groups will receive aerobic training on a treadmill (Moviment®) with the aid of a suspension equipment (BrainMov® Physical Activity Station). The transcranial photobiomodulation (laser diode, λ = 810 nm, beam area 0.028 cm², power of 100 mW, power density of 3.5 mW / cm², energy of 3 Joules / point and energy density of 107.1 J / cm2) will be applied on the skin / scalp and the International System 10-20 at points F7, F8 and AFz will be used as reference for irradiation. Muscular activation, heart rate variability, lung volumes and capacities, fatigability, exercise tolerance, cognition and quality of life will be evaluated before, during, at the end and after two months of rehabilitation. The treatment proposed in this study, using transcranial photobiomodulation, is expected to improve muscle, sensory, cardiorespiratory, cognitive functions and to interfere positively in the quality of life of the volunteers.

Read the detailed description

Central nervous system (CNS) diseases can be acquired (such as stroke, spinal cord injury, and traumatic brain injury) or non-acquired (such as multiple sclerosis). Many diseases that affect the CNS can be fatal or cause sequelae, which affect the sensorimotor, cardiorespiratory and the quality of life of the individual. Subjects with neurological lesions present low resistance to exercise, a factor that can be attributed to decreased muscle recruitment, oxidative and metabolic capacity reduction, low aerobic resistance and increased energy expenditure. With that in mind, treatment proposals such as aerobic training and gait training with or without weight loss can maximize and restore the individual's functional abilities through active learning. Cardiorespiratory fitness in this patient profile has benefits in terms of fatigue retardation, gait improvement and regulation of the autonomic nervous system. Aerobic exercises change the heart rhythm, increase vascularity and provide oxygen. The association of these factors promote cerebral neuroprotective effect, stimulate the production of endogenous neutrotransmitters related to general well-being and favor neuroplasticity. Low-intensity laser therapy, especially transcranial photobiomodulation, has shown benefits in animals and humans such as cognitive and memory improvement, improvement in the behavioral picture, such as attenuation of depression and anxiety, and cortical oxygenation.

The study design is a randomized, double-blind, placebo-controlled trial that will compare the effect of cardiorespiratory rehabilitation, cardiorespiratory rehabilitation and low-intensity laser therapy, cardiorespiratory rehabilitation and placebo laser. It is worth mentioning that the use of a Placebo Therapy is restricted to Low Power Laser irradiation. This means that the three experimental groups will effectively be treated with cardiorespiratory rehabilitation, a therapy that improves physical fitness. The treatment with transcranial photobiomodulation irradiation aims to verify the effects and aggregates greater beneficial to the volunteers. In this case, the magnitude of the laser effect must be calculated by the difference (if any) of the group treated with "cardiorespiratory rehabilitation + laser" subtracted from the group treated with "cardiorespiratory rehabilitation + laser Placebo".

02

Conditions studied

  • Post Stroke
  • Post-Traumatic Headache
  • Spinal Injuries
  • Cerebral Palsy, Spastic
  • Surgery
  • Sclerosis, Multiple
  • Spastic

Keywords

  • Neurological Diseases
  • Cardiorespiratory Rehabilitation
  • Aerobic exercise
  • Fotobiomodulação Transcraniana
03

In context

Post-Traumatic Headache

192 studies on the registry are indexed under Post-Traumatic Headache; 54 are open to participants now.

This study's planned enrollment of 90 is above the median of 44 across 169 interventional studies indexed under Post-Traumatic Headache.

Browse Post-Traumatic Headache studies →

Lead sponsor

Universidade do Vale do Paraíba is the lead sponsor of 17 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Persons with stroke, traumatic brain injury, spinal cord trauma, post-operative brain tumor, chronic non-progressive encephalopathy and multiple sclerosis;
  • Chronic neurological diseases, from 6 months of injury;
  • Caucasian individuals;
  • Age between 18 and 85 years;
  • Both sexes;
  • Individuals with the cognitive preserved;
  • Persons who are able to wander on the treadmill voluntarily or through assistance from the Rehabilitation and Physical Activity Station BrainMov®;
  • Persons who make continuous and regular use of medications prescribed by the physician for the control and / or treatment of chronic diseases;
  • People with the release of the cardiologist for rehabilitation.

Exclusion criteria

Exclusion Criteria:

  • People who do not meet the inclusion criteria;
  • Active smokers;
  • Carriers of chronic respiratory diseases, such as , asthma and bronchiectasis;
  • Patients with decompensated heart disease;
  • Obesity grade II - greater than 34.99 kg / m2;
  • Patients with spinal cord injury above T6, who present autonomic dysreflexia;
  • Patients with ASA A or B spinal cord injury;
  • Patients with multiple sclerosis who are in an outbreak period;
  • Patients taking betablockers;
  • Hemorrhagic stroke.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Control-Cardiorespiratory Rehabilitation

    These individuals will compose the control group for transcranial laser therapy, which will only receive cardiorespiratory rehabilitation.

    Procedure: Cardiorespiratory Rehabilitation

  • Placebo comparator
    Transcranial Photobiomodulation Placebo

    In this group, the application of laser irradiation will be simulated, and the laser will be turned off. And the simulation of irradiation, the individuals will initiate cardiorespiratory rehabilitation.

    Procedure: Transcranial Photobiomodulation (Placebo) · Procedure: Cardiorespiratory Rehabilitation

  • Experimental
    Transcranial Photobiomodulation

    In this group, low-intensity irradiation will be applied and after irradiation, the volunteers will begin cardiorespiratory rehabilitation.

    Procedure: Transcranial Photobiomodulation · Procedure: Cardiorespiratory Rehabilitation

Interventions

  • ProcedureTranscranial Photobiomodulation

    Photobiomodulation Rehabilitation: Diode laser, λ infrared = 810 nm, 0.028 cm2 beam area, 100 mW power, 3.5 W / cm2 power density, 3 Joules / dot and Energy Density of 107.1 J / cm2). Each point will be radiated for 30 seconds. The regions of irradiation will be in the middle cerebral arteries (points F7 and F8 will be used as reference point according to the International System 10-20 of the electroencephalogram) and anterior cerebral artery (AFz point according to the International System 10-20 of the electroencephalogram) .

  • ProcedureTranscranial Photobiomodulation (Placebo)

    Photobiomodulation Placebo Therapy: The same apparatus of the transcranial group photobiomodulation and the same irradiation points will be used. However, during the procedure, with the laser off.

  • ProcedureCardiorespiratory Rehabilitation

    Cardiorespiratory Rehabilitation: Aerobic training on the treadmill will be reliated for 30 minutes using the support of the Rehabilitation and Physical Activity Station BrainMov® (equipment with 4 pillars condition that favors the suspension and stabilization of people with neuromuscular dysfunctions of mild to severe impairment. For monitoring, the training heart rate equation - Karvonen equation, effort perception scale - BORG, systemic arterial pressure, peripheral oxygen saturation, and patient signs and symptoms will be used. Subsequently, respiratory exercises and muscle strengthening of lower limbs, final relaxation and general guidelines will be performed for research volunteer and his / her relatives.

06

What researchers measure

Primary outcomes

  1. Change in Muscular electrical activity (Surface electromyograph).

    The surface electrodes will be positioned in the rectus femoris and femoral biceps muscles. The evaluation of the muscles will be realized during the squat movement. 10 seconds of signal collection (in triplicate).

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  2. Change in analysis of bipodal balance during the squat movement.

    The balance evaluation will be performed during the squat movement on the power platform (Stabilometric analysis in Kgf). 10 seconds of signal collection (in triplicate).

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  3. Change in analysis of the heart rate variability to study the responses of the autonomic nervous system

    Heart rate variability will be assessed during aerobic training on the treadmill for 40 minutes (5 minutes of initial rest, 30 minutes of exercise and 5 minutes of final rest).

    Time frame: Baseline (First day of rehabilitation) and after 9 weeks (Last day of rehabilitation).

  4. Change in Pulmonary function analysis (spirometry): forced vital capacity

    Using the spirometry technique, forced vital capacity (measured in liters) will be evaluated. The volunteer will be asked to perform the maximum inspiration and exhale with maximum effort.

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  5. Change in Pulmonary function analysis (spirometry): forced expiratory volume in the first second

    Using the spirometry technique, forced expiratory volume in the first second (measured in liters) will be evaluated. The volume of exhaled air in the first second in the forced vital capacity maneuver will be evaluated.

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  6. Change in Pulmonary function analysis (spirometry): Tiffeneau Index

    Using the spirometry technique, Tiffeneau Index will be evaluated. The Tiffeneau index is the result of the division of forced expiratory volume in the first second in relation to forced vital capacity.

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  7. Change in Pulmonary function analysis (spirometry): maximum voluntary ventilation

    Using the spirometry technique, maximum voluntary ventilation will be evaluated. Maximum voluntary ventilation is the largest volume of air that the individual can mobilize in one minute with maximum voluntary effort. The test gives an overview of the ventilatory function (measured in L / min).

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  8. Change in analysis of inspiratory muscle strength

    The inspiratory muscle strength will be evaluated by means of the manovacuometer.

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  9. Analysis of expiratory muscle strength

    The expiratory muscle strength will be evaluated by means of the manovacuometer

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  10. Change in analysis of Peak expiratory flow.

    To analyze the velocity of the air out of the lungs.

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  11. Change in analysis of the thoracic expandability (axillary level).

    In order to analyze the chest expansion at the axillary level, a metric tape placed at the torarico-axillary level will be used, which will measure the inspiratory and expiration mobility values, and will be subtracted (Insp-Exp).

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  12. Change in analysis of the thoracic expandability (xiphoid level).

    In order to analyze the chest expansion at the xiphoid level, a metric tape will be used, placed at the thoracic-xiphoid level, which will measure the inspiratory and expiration mobility values and then be subtracted (Insp-Exp).

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  13. Change in analysis of abdominal level expandability.

    In order to analyze abdominal expansibility, a tape measure will be used, placed at the level of the umbilical scar, which will measure the inspiratory and expiration mobility values and will be subtracted (Insp-Exp).

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  14. Change in analysis of change in Infrared Thermography.

    By means of an infrared thermographic camera, the blood circulation of the lower limbs will be evaluated by the temperature difference.

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  15. Change in aariation of blood lactate level.

    The blood lactate level will be measured by a lactometer, which will be collected from the volunteer's blood sample before starting the aerobic training on the treadmill and after training.

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  16. Change in 6-Minute Walk Test (Adapted)

    The 6-minute-walk test will be adapted for neurological patients, which will be evaluated for exercise tolerance using a treadmill (Moviment RT200®). Volunteers will be assisted by the BrainMov® Rehabilitation and Physical Activity Station to stabilize the trunk and thus remain upright to wander on the treadmill

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  17. Change in Mini-Mental State Examination (MINI MENTAL).

    To evaluate the cognitive functions, the MINI MENTAL test will be applied.

    Time frame: Baseline (before starting rehabilitation) and after 9 weeks.

  18. Change in Short Form 36 questionnaire (SF-36)

    To evaluate the domains of quality of life: Functional Capacity, physical aspect, pain, general health, vitality, social aspect, emotional spectrum and mental health

    Time frame: Baseline (before starting rehabilitation) and after 9 week.

Secondary outcomes

  1. Follow-up: Evaluation Muscular electrical activity (Surface electromyograph)

    Evaluation of muscular electrical activity after 9 weeks of the end of rehabilitation. The surface electrodes will be positioned in the rectus femoris and femoral biceps muscles. The evaluation of the muscles will be realized during the squat movement. 10 seconds of signal collection (in triplicate).

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  2. Follow-up: Analysis of bipodal balance during the squat movement

    The balance evaluation will be performed during the squat movement on the power platform. 10 seconds of signal collection (in triplicate).

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  3. Follow-up: Analysis of the heart rate variability to study the responses of the autonomic nervous system

    The heart rate variability will be evaluated during aerobic training on the treadmill using a frequency for 5 minutes of initial rest, 30 minutes of exercise and 5 minutes of final rest.

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  4. Follow-up: Pulmonary function analysis (spirometry): forced vital capacity

    Using the spirometry technique, forced vital capacity (measured in liters) will be evaluated. The patient will be asked to perform the maximum inspiration and exhale with maximum effort.

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  5. Follow-up: Pulmonary function analysis (spirometry): forced expiratory volume in the first second

    Using the spirometry technique, forced expiratory volume in the first second (measured in liters) will be evaluated. The volume of exhaled air in the first second in the forced vital capacity maneuver will be evaluated.

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  6. Follow-up: Pulmonary function analysis (spirometry):Tiffeneau Index

    Using the spirometry technique, Tiffeneau Index will be evaluated. The Tiffeneau index is the result of the division of forced expiratory volume in the first second in relation to forced vital capacity.

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  7. Follow-up: Pulmonary function analysis (spirometry): maximum voluntary ventilation

    Using the spirometry technique, maximum voluntary ventilation will be evaluated. Maximum voluntary ventilation is the largest volume of air that the individual can mobilize in one minute with maximum voluntary effort. The test gives an overview of the ventilatory function (measured in L / min).

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  8. Follow-up: Analysis of inspiratory muscle strength

    The inspiratory muscle strength will be evaluated by means of the manovacuometer.

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  9. Follow-up: Analysis of expiratory muscle strength

    The expiratory muscle strength will be evaluated by means of the manovacuometer.

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  10. Follow-up: Analysis of Peak expiratory flow.

    To analyze the velocity of the air out of the lungs.

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  11. Follow-up: Analysis of the thoracic expandability (axillary level).

    In order to analyze the chest expansion at the axillary level, a metric tape placed at the torarico-axillary level will be used, which will measure the inspiratory and expiration mobility values, and will be subtracted (Insp-Exp).

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  12. Follow-up: Analysis of the thoracic expandability (xiphoid level).

    In order to analyze the chest expansion at the xiphoid level, a metric tape will be used, placed at the thoracic-xiphoid level, which will measure the inspiratory and expiration mobility values and then be subtracted (Insp-Exp).

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  13. Follow-up: Analysis of abdominal level expandability.

    In order to analyze abdominal expansibility, a tape measure will be used, placed at the level of the umbilical scar, which will measure the inspiratory and expiration mobility values and will be subtracted (Insp-Exp).

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  14. Follow-up: Analysis of change in Infrared Thermography.

    By means of an infrared thermographic camera, the blood circulation of the lower limbs will be evaluated by the temperature difference.

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  15. Follow-up: Variation of blood lactate level.

    The blood lactate level will be measured by a lactometer, which will be collected from the volunteer's blood sample before starting the aerobic training on the treadmill and after training.

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  16. Follow-up: Analysis 6-Minute Walk Test (Adapted)

    The 6-minute-walk test will be adapted for neurological patients, which will be evaluated for exercise tolerance using a treadmill (Moviment RT200®). Volunteers will be assisted by the BrainMov® Rehabilitation and Physical Activity Station to stabilize the trunk and thus remain upright to wander on the treadmill.

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  17. Follow-up: Evaluation Mini-Mental State Examination (MINI MENTAL).

    To evaluate the cognitive functions, the MINI MENTAL test will be applied.

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

  18. Follow-up: Evaluation Short Form 36 questionnaire (SF-36)

    To evaluate the domains of quality of life: Functional Capacity, physical aspect, pain, general health, vitality, social aspect, emotional spectrum and mental health

    Time frame: The follow-up revaluation will be 2 months after the end of rehabilitation.

07

Study locations

1 site
  • Universidade do Vale do Paraíba
    São José Dos Campos, São Paulo 12244-000, Brazil
08

References and documents

Publications

  • Pinto AP, Guimaraes CL, Souza GADS, Leonardo PS, Neves MFD, Lima FPS, Lima MO, Lopes-Martins RAB. Sensory-motor and cardiorespiratory sensory rehabilitation associated with transcranial photobiomodulation in patients with central nervous system injury: Trial protocol for a single-center, randomized, double-blind, and controlled clinical trial. Medicine (Baltimore). 2019 Jun;98(25):e15851. doi: 10.1097/MD.0000000000015851. PubMed 31232920 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2019; primary completion for Jul 2019, 6 months later.

Of 89 non-industry interventional studies with no phase under Post-Traumatic Headache, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 6 months is below that.

Counting every sponsor, half of 90 studies reached it within 12 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2018
First posted
Nov 23, 2018
StartEst.
Jan 14, 2019
Primary completionEst.
Jul 31, 2019
CompletionEst.
Mar 5, 2020
Last update
Nov 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03751306
Lead sponsor
Universidade do Vale do Paraíba
Responsible party
Sponsor
First posted
Nov 23, 2018
Start date
Jan 14, 2019 (estimated)
Primary completion
Jul 31, 2019 (estimated)
Completion
Mar 5, 2020 (estimated)
Last update
Nov 27, 2018

Study contacts

Ana Paula Pinto
Contact
apaula@outlook.com.br
55 12 981585974
Carolina Lobo Guimarães
Contact
caroll.guimaraes@yahoo.com.br
55 12 981585974
Mário Oliveira Lima, Doctor
principal investigator · Universidade do Vale do Paraíba - Univap

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion